Eisai Files Application Seeking Additional Indication for ARICEPT in Europe.
The company intends to seek approval in 12 European countries under the Mutual Recognition procedure.
Eisai expects that ARICEPT will become available for the treatment of severe Alzheimer's disease. Currently, about 4.5 million people have Alzheimer's disease in Europe.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||May 17, 2006|
|Previous Article:||Hitachi Develops Innovative Mass Spectrometry Method for Improving Accuracy in Protein Analysis.|
|Next Article:||Olympus to Release Special Reagent Kit for Its Single Molecular Fluorescence Spectroscopy MF20.|